Zalicus Inc. and Epirus Biopharmaceuticals, Inc. agreed that Zalicus stockholders will own 19% of the combined company post-merger. In addition, Dr. Mark H.N. Corrigan will serve as chairman of the company's board of directors, which will have representatives from both the existing Epirus and Zalicus boards.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 26 | |
+33.88% | 51.51B | |
-6.70% | 39.03B | |
+34.46% | 38.91B | |
-10.62% | 26.68B | |
+11.39% | 26.13B | |
-15.25% | 19.91B | |
+41.93% | 13.71B | |
+31.10% | 12.38B | |
-3.38% | 11.74B |
- Stock Market
- Equities
- EPRSQ Stock
- News EPIRUS Biopharmaceuticals, Inc.
- Epirus Biopharmaceuticals, Inc. Appoints Mark H.N. Corrigan to Board of Directors